Skip to main content

Table 1 Baseline characteristics for training and test datasets

From: Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study

 

Placebo + MTX

Golimumab 100 mg + placebo

Golimumab 50 mg + MTX

Golimumab 100 mg + MTX

Total

Training dataset

     

Number

21

30

21

28

100

Age (years)

50 ± 12

(24-76)

50 ± 12

(22-71)

53 ± 11

(25-68)

52 ± 9

(38-76)

51 ± 11

(22-76)

Weight (kg)

70 ± 13

(47-97)

72 ± 15

(47-104)

69 ± 18

(43-108)

75 ± 22

(47-120)

72 ± 17

(43-120)

Sex (% men)

10%

20%

10%

21%

16%

Race (% Caucasian)

76%

67%

67%

75%

71%

CRP (μg/ml)

1.97 ± 2.54

(0.3-10.8)

2.16 ± 2.77

(0.3-11.7)

1.20 ± 1.53

(0.3-7.0)

1.38 ± 1.44

(0.3-6.2)

1.70 ± 2.18

(0.30-11.7)

Swollen joint count

13.0 ± 5.7

(5-26)

13.9 ± 10.4

(5-51)

12.5 ± 9.2

(4-48)

14.2 ± 9.6

(5-43)

13.5 ± 9.0

(4-51)

Tender joint count

21.3 ± 12.3

(6-62)

21.4 ± 13.1

(5-58)

23.2 ± 16.8

(4-63)

24.1 ± 13.4

(6-53)

22.5 ± 13.7

(4-63)

FACIT-F (0-52)

 

26 ± 11

(4-50)

26 ± 10

(4-50)

27 ± 12

(12-50)

26 ± 11

(4-50)

SF-36 mental component summary score (0-100)

 

44 ± 9

(20-61)

45 ± 11

(26-61)

44 ± 11

(24-62)

44 ± 10

(20-62)

SF-36 physical component summary score (0-100)

 

30 ± 8

(17-54)

32 ± 9

(18-51)

33 ± 8

(19-52)

31 ± 8

(17-54)

Test dataset

     

Number

N/A

102

68

66

236

Age (years)

 

50 ± 11

(21-74)

50 ± 11

(18-79)

50 ± 10

(23-72)

50 ± 11

(18-79)

Weight (kg)

 

74 ± 17

(42-135)

74 ± 18

(39-146)

71 ± 17

(40-136)

73 ± 17

(39-146)

Sex (% men)

 

22%

22%

21%

22%

Race (% Caucasian)

 

82%

76%

82%

81%

CRP (μg/ml)

 

1.84 ± 2.27

(0.3-15.1)

2.23 ± 2.54

(0.3-11.5)

1.98 ± 2.68

(0.3-16.8)

1.99 ± 2.47

(0.3-16.8)

Swollen/tender joint count

 

41.0 ± 21.6

(10-88)

47.4 ± 23.0

(10-105)

41.7 ± 21.0

(9-100)

43.0 ± 21.9

(9-105)

Swollen joint count

 

15.0 ± 10.6

(4-59)

18.0 ± 12.3

(4-53)

14.8 ± 9.7

(4-45)

15.8 ± 10.9

(4-59)

Tender joint count

 

26.0 ± 15.9

(5-68)

29.3 ± 15.3

(5-68)

27.0 ± 15.0

(4-62)

27.2 ± 15.5

(4-68)

FACIT-F (0-52)

 

29 ± 11

(5-50)

27 ± 11

(6-50)

26 ± 10

(6-47)

27 ± 11

(5-50)

SF-36 mental component summary score (0-100)

 

44 ± 12

(19-73)

44 ± 11

(19-73)

43 ± 12

(17-68)

43 ± 11

(17-73)

SF-36 physical component summary score (0-100)

 

31 ± 9

(15-54)

30 ± 8

(16-49)

29 ± 8

(12-46)

30 ± 8

(12-54)

  1. Values are expressed as mean ± standard deviation (range), unless otherwise indicated. CRP, C-reactive protein; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; MTX, methotrexate; SF-36, 36-question Short Form Survey.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us